Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer

Figure 1 Five-year overall survival of gastric cancer patients based on hepatoduodenal lymph node metastasis. A: All 276 patients analysed in this study were divided into two groups based on hepatoduodenal lymph node (HDLN) metastasis. A group with HDLN metastasis (n = 26) and that without HDLN metastasis (n = 250) were compared. Kaplan-Meier survival curves were statistically analysed by the log-rank test (P < 0.0001); B: The patients who had lymph node metastasis (n = 145) were divided into two groups and analysed as described in panel a (26 patients with HDLN metastasis and 119 patients without HDLN metastasis, P < 0.0001).

Figure 2 Five-year overall survival curves of gastric cancer patients based on the extent of lymph node metastasis. A: Twenty-six patients who had hepatoduodenal lymph node (HDLN) metastasis were divided into two groups based on the extent of lymph node metastasis. A group of pathological (p)N1 or N2 (n = 10) and that of pN3 (n = 16) were compared as described in Figure 1 (P = 0.0024); B: All 82 pN1 or N2 patients were divided into two groups based on HDLN metastasis and analysed as described in Figure 1 (10 patients with HDLN metastasis and 72 patients without HDLN metastasis, P = 0.602); C: All 63 pN3 patients were analysed as described in Figure 1 (16 patients with HDLN metastasis and 47 patients without HDLN metastasis, P < 0.0001).